Involvement of receptor-bound prorenin in development of nephropathy in diabetic db/db mice

Atsuhiro Ichihara, Mariyo Sakoda, Asako Kurauchi-Mito, Akira Nishiyama, Hiroshi Itoh

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Previous studies have demonstrated that prorenin plays a significant role in the development and progression of nephropathy in streptozotocin-induced diabetic animals, a model for type 1 diabetes, through a (pro)renin receptor-dependent mechanism. However, whether this novel mechanism also contributes to the mechanism of diabetic nephropathy in type 2 diabetes has remained undetermined. In 16-week-old db/db mice, a model for type 2 diabetes, we found a significant degree of glomerulosclerosis, enhanced immunostaining for the active site of renin (representing non-proteolytically activated prorenin), and an increased immunoreactivity to activated extracellular-signal-related protein kinase 1/2 in the kidneys. These changes were blocked by the chronic subcutaneous administration (1 mg/kg/day) of a decoy peptide with the "handle region" structure, which competitively inhibits prorenin binding to a "handle region"-specific binding protein, such as the (pro)renin receptor. The kidneys of db/db mice also contained increased angiotensin (Ang) I and II levels, eliciting significant microalbuminuria. Treatment with the "handle region" peptide significantly decreased the renal content of Ang I and II and inhibited the development of microalbuminuria. Thus prorenin also contributes to the development of nephropathy in type II diabetes, probably through a (pro)renin receptor-dependent mechanism.

Original languageEnglish
Pages (from-to)332-340
Number of pages9
JournalJournal of the American Society of Hypertension
Volume2
Issue number5
DOIs
Publication statusPublished - 2008 Sep

Fingerprint

Diabetic Nephropathies
Renin
Type 2 Diabetes Mellitus
Angiotensin I
Kidney
Angiotensin II
Peptides
prorenin receptor
Streptozocin
Type 1 Diabetes Mellitus
Protein Kinases
Catalytic Domain
Carrier Proteins
Animal Models

Keywords

  • Albuminuria
  • angiotensin
  • glomerulosclerosis
  • type 2 diabetes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Involvement of receptor-bound prorenin in development of nephropathy in diabetic db/db mice. / Ichihara, Atsuhiro; Sakoda, Mariyo; Kurauchi-Mito, Asako; Nishiyama, Akira; Itoh, Hiroshi.

In: Journal of the American Society of Hypertension, Vol. 2, No. 5, 09.2008, p. 332-340.

Research output: Contribution to journalArticle

Ichihara, Atsuhiro ; Sakoda, Mariyo ; Kurauchi-Mito, Asako ; Nishiyama, Akira ; Itoh, Hiroshi. / Involvement of receptor-bound prorenin in development of nephropathy in diabetic db/db mice. In: Journal of the American Society of Hypertension. 2008 ; Vol. 2, No. 5. pp. 332-340.
@article{675a2b643c96417aa73ccc8662f66e9d,
title = "Involvement of receptor-bound prorenin in development of nephropathy in diabetic db/db mice",
abstract = "Previous studies have demonstrated that prorenin plays a significant role in the development and progression of nephropathy in streptozotocin-induced diabetic animals, a model for type 1 diabetes, through a (pro)renin receptor-dependent mechanism. However, whether this novel mechanism also contributes to the mechanism of diabetic nephropathy in type 2 diabetes has remained undetermined. In 16-week-old db/db mice, a model for type 2 diabetes, we found a significant degree of glomerulosclerosis, enhanced immunostaining for the active site of renin (representing non-proteolytically activated prorenin), and an increased immunoreactivity to activated extracellular-signal-related protein kinase 1/2 in the kidneys. These changes were blocked by the chronic subcutaneous administration (1 mg/kg/day) of a decoy peptide with the {"}handle region{"} structure, which competitively inhibits prorenin binding to a {"}handle region{"}-specific binding protein, such as the (pro)renin receptor. The kidneys of db/db mice also contained increased angiotensin (Ang) I and II levels, eliciting significant microalbuminuria. Treatment with the {"}handle region{"} peptide significantly decreased the renal content of Ang I and II and inhibited the development of microalbuminuria. Thus prorenin also contributes to the development of nephropathy in type II diabetes, probably through a (pro)renin receptor-dependent mechanism.",
keywords = "Albuminuria, angiotensin, glomerulosclerosis, type 2 diabetes",
author = "Atsuhiro Ichihara and Mariyo Sakoda and Asako Kurauchi-Mito and Akira Nishiyama and Hiroshi Itoh",
year = "2008",
month = "9",
doi = "10.1016/j.jash.2008.04.009",
language = "English",
volume = "2",
pages = "332--340",
journal = "Journal of the American Society of Hypertension",
issn = "1933-1711",
publisher = "Elsevier Ireland Ltd",
number = "5",

}

TY - JOUR

T1 - Involvement of receptor-bound prorenin in development of nephropathy in diabetic db/db mice

AU - Ichihara, Atsuhiro

AU - Sakoda, Mariyo

AU - Kurauchi-Mito, Asako

AU - Nishiyama, Akira

AU - Itoh, Hiroshi

PY - 2008/9

Y1 - 2008/9

N2 - Previous studies have demonstrated that prorenin plays a significant role in the development and progression of nephropathy in streptozotocin-induced diabetic animals, a model for type 1 diabetes, through a (pro)renin receptor-dependent mechanism. However, whether this novel mechanism also contributes to the mechanism of diabetic nephropathy in type 2 diabetes has remained undetermined. In 16-week-old db/db mice, a model for type 2 diabetes, we found a significant degree of glomerulosclerosis, enhanced immunostaining for the active site of renin (representing non-proteolytically activated prorenin), and an increased immunoreactivity to activated extracellular-signal-related protein kinase 1/2 in the kidneys. These changes were blocked by the chronic subcutaneous administration (1 mg/kg/day) of a decoy peptide with the "handle region" structure, which competitively inhibits prorenin binding to a "handle region"-specific binding protein, such as the (pro)renin receptor. The kidneys of db/db mice also contained increased angiotensin (Ang) I and II levels, eliciting significant microalbuminuria. Treatment with the "handle region" peptide significantly decreased the renal content of Ang I and II and inhibited the development of microalbuminuria. Thus prorenin also contributes to the development of nephropathy in type II diabetes, probably through a (pro)renin receptor-dependent mechanism.

AB - Previous studies have demonstrated that prorenin plays a significant role in the development and progression of nephropathy in streptozotocin-induced diabetic animals, a model for type 1 diabetes, through a (pro)renin receptor-dependent mechanism. However, whether this novel mechanism also contributes to the mechanism of diabetic nephropathy in type 2 diabetes has remained undetermined. In 16-week-old db/db mice, a model for type 2 diabetes, we found a significant degree of glomerulosclerosis, enhanced immunostaining for the active site of renin (representing non-proteolytically activated prorenin), and an increased immunoreactivity to activated extracellular-signal-related protein kinase 1/2 in the kidneys. These changes were blocked by the chronic subcutaneous administration (1 mg/kg/day) of a decoy peptide with the "handle region" structure, which competitively inhibits prorenin binding to a "handle region"-specific binding protein, such as the (pro)renin receptor. The kidneys of db/db mice also contained increased angiotensin (Ang) I and II levels, eliciting significant microalbuminuria. Treatment with the "handle region" peptide significantly decreased the renal content of Ang I and II and inhibited the development of microalbuminuria. Thus prorenin also contributes to the development of nephropathy in type II diabetes, probably through a (pro)renin receptor-dependent mechanism.

KW - Albuminuria

KW - angiotensin

KW - glomerulosclerosis

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=51449113656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51449113656&partnerID=8YFLogxK

U2 - 10.1016/j.jash.2008.04.009

DO - 10.1016/j.jash.2008.04.009

M3 - Article

VL - 2

SP - 332

EP - 340

JO - Journal of the American Society of Hypertension

JF - Journal of the American Society of Hypertension

SN - 1933-1711

IS - 5

ER -